Canadian Osteoporosis Screening Guidelines
The 2023 Canadian Task Force on Preventive Health Care recommends a "risk assessment-first" approach: screen women aged 65 years and older using the Canadian FRAX tool (without BMD initially) to facilitate shared decision-making about pharmacotherapy, then order DXA testing only if pharmacotherapy is being considered to re-estimate fracture risk with BMD input. 1, 2
Screening Recommendations by Population
Women ≥65 Years
- Screen all women aged 65 years and older using the Canadian FRAX tool without bone mineral density (BMD) input as the initial step 1, 2
- Use the FRAX result to facilitate shared decision-making about potential benefits and harms of preventive pharmacotherapy 2
- Only proceed to DXA testing of the femoral neck if pharmacotherapy is being considered after the shared decision-making discussion 2
- Re-calculate fracture risk by adding the BMD T-score into FRAX after DXA is performed 2
Women <65 Years
- Recommend against routine screening in women aged 40-64 years (strong recommendation, very low-certainty evidence) 1, 2
- This represents a significant departure from some other guidelines and emphasizes clinical vigilance rather than systematic screening in this age group 2
Men ≥40 Years
- Recommend against routine screening in men aged 40 years and older (strong recommendation, very low-certainty evidence) 1, 2
- This recommendation applies to community-dwelling men not currently on preventive pharmacotherapy 2
Key Differences from Other Guidelines
The Canadian approach differs notably from US guidelines, which recommend DXA screening for all women ≥65 years and selective screening for younger postmenopausal women with risk factors 1. The Canadian "risk assessment-first" strategy delays DXA until after initial fracture risk assessment and shared decision-making, potentially reducing unnecessary testing 2.
Screening Intervals
- No specific screening interval is established in the Canadian guidelines 1
- The evidence on optimal rescreening intervals remains limited and requires individualized clinical judgment 1
Treatment Thresholds
The 2023 Osteoporosis Canada clinical practice guideline bases treatment decisions on: 3, 4
- 10-year major osteoporotic fracture (MOF) risk calculated using FRAX
- BMD T-score from DXA
- Age of the patient
- Fracture history
Management should incorporate exercise, nutrition, and pharmacotherapy as key elements for fracture prevention 3.
Important Clinical Caveats
- These recommendations apply only to community-dwelling individuals not currently on preventive pharmacotherapy 2
- The recommendations do not apply to individuals with medical conditions or taking medications associated with bone loss (such as glucocorticoid users), who require different management approaches 1
- Clinicians must remain alert to clinical changes indicating increased fracture risk even in populations where routine screening is not recommended 2
Rationale for the Canadian Approach
The risk assessment-first strategy allows patients to consider preventive pharmacotherapy within their individual risk context before undergoing DXA testing 2. This approach emphasizes shared decision-making and may improve resource utilization by reserving DXA for those most likely to benefit from the additional information it provides 2.